Memokath® 044TW Stent for Treatment of Urethral Stricture

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-12-31

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate if the placement of a temporary urethral stent for up to 12 months, following dilation or internal urethrotomy (cutting open), results in a higher rate of urethral patency during the first year of follow-up when compared to the control group that does not receive a stent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tissue-engineered Construct Based on Buccal Mucosa Cells and Matrix From Collagen and Polylactoglycolide Fibers

NCT03205670

Urethral Stricture

UNKNOWN EARLY_PHASE1

Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy

NCT05857371

Urethral Stenosis

RECRUITING PHASE2

Clostridium Histolyticum Collagenase Injection for Urethral Disease

NCT02948842

Urethral Stricture

COMPLETED PHASE2

A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas

NCT05641844

Anal Fistula

RECRUITING NA

Effectiveness and Safety of Autologous Adipose-Derived Regenerative Cells for the Treatment of Urethral Strictures

NCT01889888

Urethral Strictures in Males

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with bulbar urethral stricture are 2:1 randomised for either urethral dilation or internal urethrotomy with (treatment group) or without (control group) subsequent stenting. All patients are followed for up to one year at 4-6 weeks, 3, 6, 9 and 12 months with visual assessment (urethroscopy) of urethral patency at the treated segment of the urethra. The stent is removed at one year. In case of premature stent removal the patient is also followed for up to one year unless further intervention is decided.

Control patients are offered the stent treatment option if the stricture recurs within the observation period but this group is separately analysed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urethral Stricture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Memokath stenting

Urethral Stenting

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males \> 21 years of age
2. Recurrent stricture of the bulbar urethra:

1. \< 50 mm in length on urethrography; and which
2. has a segment unable to accommodate a 16Fr flexible cystoscope
3. Healthy tissue on both sides of stent
4. Urinary flow in the abnormal range of the Siroky nomogram.
5. Written informed consent obtained prior to participation in the study
6. Patients must be available for all follow-up visits.

Exclusion Criteria

1. Strictures:

1. outside the bulbous urethra
2. associated with, or suspected to be, urethral carcinoma
3. secondary to pelvic distraction injuries
2. Inability to enlarge the bulbar urethral stricture to \> 26 Fr.
3. Presence of any other urologic implant
4. Presence of urethral diverticuli
5. History of hypospadias repair
6. Presence or prior history of balanitis xerotica obliterans.
7. Uncontrolled bleeding disorder
8. Active urinary tract infection
9. Any urological condition that would be likely to require additional urethral instrumentation during the period of the investigation, including, but not limited to, benign prostatic hypertrophy requiring treatment; use of alpha blockers; active prostate cancer; an unevaluated elevated prostate-specific antigen (PSA); bladder malignancy; or any recurrent urinary stone formation.
10. Serum creatinine \> 2.0 mg/dl or evidence of progressive renal disease
11. Concurrent participation in another clinical investigation
12. Current illness that might confound the results of this investigation
13. Inability to participate in all of the necessary study activities
14. Inability or unwillingness to return for all required follow-up visits
15. Inability or unwillingness to sign the patient informed consent document

Minimum Eligible Age

21 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No